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Genes make their position clear
C
ertain genes switch 
their nuclear po-
sition in tumor 
cells, offering a potential 
new method of diagnosing 
cancer, say Meaburn et al.
Individual genes pref-
erentially localize to specifi  c 
points within the nucleus. 
The reasons for this aren’t known, but the positions can be 
reshuffled during differentiation. Meaburn et al. wondered 
whether genes might also rearrange during carcinogenesis, 
when large-scale changes in nuclear morphology occur. The 
researchers previously identified four genes that shift their 
location in a 3D culture model of early breast cancer, and 
now turned their attention to human tissue.
The team analyzed 20 genes and found that most were 
positioned uniformly in healthy breast tissue from numerous 
individuals. Eight of these genes consistently relocated in the 
nuclei of invasive breast cancer cells, including HES5, which had 
an altered localization in all tumors examined. The researchers 
were able to distinguish between normal and diseased tissue on 
the sole basis of these genes’ nuclear localization with success 
rates similar to current clinical tests.
The next step, says lead author Karen Meaburn, will be to 
repeat the study on a larger number of samples. HES5 is unlikely 
to be repositioned in all of these, so the authors hope to identify a 
set of genes that, in combination, can accurately diagnose breast 
cancer. The approach may be useful for prognosis, too—in vitro 
studies suggest that gene movements are an early event in cancer 
development, so gene positions might provide an indication of 
the cancer’s future progress.
Meaburn, K.J., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200909127.
I
t’s important to fi  nish what you 
start, say Ju et al., who reveal 
how a mutant ATPase blocks 
autophagy partway through to cause a 
multi-tissue degenerative disease.
Mutations in VCP, a member of 
the AAA ATPase family, cause inclu-
sion body myopathy, Paget’s disease 
of the bone, and frontotemporal 
dementia (IBMPFD), a rare disorder 
that mainly affects skeletal muscle, 
brain, and bone. Patient muscle contains aggregates of membrane 
and proteins called rimmed vacuoles, which accumulate and disrupt 
cellular architecture. This pileup of membranous trash is inconsistent 
with VCP’s known involvement in proteasome-mediated protein 
degradation. Ju et al. thus wondered whether the ATPase might 
also be involved in garbage disposal via the autophagy pathway.
Knocking down or expressing mutated VCP in cells increased 
levels of the autophagy markers p62 and LC3. Microscopy revealed 
that although autophagosomes containing these two proteins formed, 
they failed to mature into autolysosomes capable of degradation. 
VCP mutant mice and IBMPFD patients also accumulated p62 and 
LC3 in their muscle, and the two proteins localized to rimmed vacu-
oles, suggesting that the membrane–protein aggregates arise from 
frustrated autophagosomes. Indeed, injecting wild-type mice with a 
drug that blocks autophagosome maturation also produced rimmed 
vacuoles, as well as inducing other markers of IBMPFD myopathy.
The researchers now want to determine the mechanism by 
which VCP promotes the fi  nal stages of autophagy and how this is 
perturbed in IBMPFD patients. However, senior author Chris Weihl 
points out that many therapies being developed to treat degenerative 
diseases attempt to rescue cells by stimulating autophagy. In the case 
of IBMPFD, this could make matters worse, as autophagy has no 
problem initiating—it’s the failure to fi  nish that causes the problem.
Ju, J.-S., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200908115.
VCP takes out the trash
Membranous vacuoles corre-
sponding to nondegradative 
autophagosomes accumu-
late in muscle expressing 
mutated VCP.
Membranes enter transfer negotiations
A 
family of yeast proteins 
can bridge adjacent mem-
branes and transfer sterol 
lipids between them, say Schulz et 
al. The process may allow one organ-
elle to regulate the lipid composi-
tion of another.
To maintain the correct level 
of sterols that they need to func-
tion, organelles exchange the lipids 
through vesicular and nonvesicular pathways. In yeast, the latter 
mechanism requires the Osh family of sterol-binding proteins and 
is thought to occur at membrane contact sites, where organelles 
are positioned extremely close to each other. How Osh proteins 
facilitate lipid transfer is unknown, however.
Schulz et al. discovered that Osh proteins can bind two dif-
ferent organelles simultaneously, due to the existence of distinct 
membrane-binding domains on either side of their structure. One 
of these domains is next to the protein’s sterol-binding pocket, and 
probably positions the pocket so it can easily extract a sterol 
molecule or deliver it to a target membrane. But the other site may 
regulate this process by interacting with phospholipids in another 
membrane close by. When the second site was mutated in Osh4p, 
the protein could still transfer sterols between liposomes in vitro 
but—unlike the wild-type protein—the rate of exchange wasn’t 
enhanced by the presence of PI(4,5)P  2  . Moreover, Osh4p lacking the 
second membrane-binding site couldn’t transfer sterol in cells.
The researchers found that most Osh proteins localize to 
membrane contact sites, where they likely transfer sterols between 
closely apposed organelles. The direction of transfer might be con-
trolled by the phospholipids in each membrane, says senior author 
William Prinz, if the protein prefers to release sterol when its second 
membrane-binding site is contacting a particular phosphoinositide.
Schulz, T.A., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200905007.
Genes including ERBB2 (green) and 
MYC (red) are positioned differently 
in normal (left) and cancerous (right) 
tissue.
Osh2p (green) is enriched 
where the ER (red) is close 
to the plasma membrane.